v" Within 4 weeks after definitive surgery, 91 patients with supratentorial glioblastomas and malignant astrocytomas were randomized to one of three treatment arms: Group 1 received radiotherapy alone; Group 2 received dibromodulcitol (DBD) during radiotherapy, and treatment was then continued with DBD; and Group 3 received DBD during radiotherapy, followed by combination chemotherapy of CCNU and DBD. No severe myelotoxicity occurred, but combined treatment with CCNU and DBD occasionally caused a transient myelosuppression. Statistical analysis of 84 evaluable patients showed a significantly longer survival period in those who received chemotherapy during and after irradiation. Median survival times in the three groups were 40, 57, and 60 weeks, respectively; the corresponding p value for Groups 2 and 3 was 0.025 and 0.0015. The ratio of patients surviving over 18 and 24 months was highest in Group 3. This study suggests that the administration of DBD during irradiation might have been the main factor in improving survival times.
T HE beneficial effect of postoperative radiotherapy in patients with malignant glioma has been demonstrated, and a median survival time of 7 to 9 months has been achieved. Adjuvant chemotherapy with various drugs applied during and/or after irradiation has been only slightly more effective. Even the extensive use of the drugs believed to be most active, namely, different nitrosoureas, increased survival times only marginally. 1o. 15, 16 Hexitol derivatives such as dibromodulcitol (DBD, Mitolactol, NSC-104800) and dianhydrogalactitol (DAG) are widely used in the treatment of various malignancies but have rarely been prescribed for brain-tumor therapy. 1-3.6,7 In our previous pilot Phase II study performed with DBD and irradiation, we achieved a median survival time of 50.5 weeks for glioblastoma patients. 1 This prompted us to carry out a Phase III trial to obtain further information about the activity of DBD in the treatment of malignant gliomas.
Clinical Material and Methods

Patient Population
This series includes 91 patients who were operated on between October, 1978, and February, 1981 , for malignant supratentorial gliomas at the National Institute of Neurosurgery, Budapest (85 cases) and at the Neurosurgical Department of the County Hospital, Miskolc (six cases). These patients met our criteria for eligibility, which were as follows: 1) definitive surgery with at least a subtotal tumor resection; 2) histological diagnosis of glioblastoma or malignant astrocytoma Grade 3; 3) Karnofsky Performance Scale score of 60 or more at the end of the 4th week; 4) a minimum life expectancy of more than 2 months; 5) normal hematopoetic, renal, and liver functions and no major illnesses other than the brain neoplasm; and 6) the consent of the patient to the planned treatment. These patients were randomized to one of three treatment arms within 4 weeks following their operation.
Treatment
The 85 patients treated at Budapest received nearly uniform high-voltage cobalt-60 radiotherapy with the same equipment, through two to three large portals directed at the extended operative field. The average dose of irradiation was 51 Gy, given in five fractions per week (approximately 1.7 to 2.0 Gy/day) over 5 to 6 weeks, in one course without interruption (Table 1) . Patients randomized to receive radiotherapy only (Group 1) received no other treatment but underwent careful review at 3-month intervals. In the second arm of the study (Group 2), we administered DBD during radiotherapy in a single dose of 400 mg/sq m every 5th day, for a total of six to eight doses. After a rest of 4 to 6 weeks, oral DBD treatment was continued according to the same schedule. One course consisted of seven doses (400 mg]sq m every 5th day) and lasted for 1 month. Following a rest period of 4 to 6 weeks, DBD courses were repeated either until severe deterioration of the patient or for 18 months.
Patients designated to the third arm of the protocol (Group 3) received the same dose of radiotherapy and DBD during irradiation as described for Group 2. After a cessation of therapy for 5 to 6 weeks, a course of combined chemotherapy was started, as follows: CCNU (1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea) was administered on Day 1 in a single dose of 80 to 100 mg/ sq m; from Day 2 DBD was given every 5th day in a single dose of 200 mg/sq m for seven doses. One cycle took 32 days to complete, and was followed by a rest period of 4 to 6 weeks. Thereafter, similar courses of CCNU and DBD were repeated either until severe deterioration of the patient or for 18 months.
Continuous use of corticosteroids was permitted only in certain cases during irradiation, and then at a minimal level (1.5 to 3.0 rag/day dexamethasone). Corticosteroid therapy was not used routinely during the preand immediate postoperative period. Irradiation was started in all groups within 2 to 5 weeks after surgery.
Clinical and Statistical Evaluation
All patients who received chemotherapy during and after irradiation were checked every 2 to 4 weeks for complete blood counts and for hepatic and renal function. Every 8 to 10 weeks neurological examination, and isotope brain scans and/or computerized tomography (CT) scans were performed. Angiography was carried out only exceptionally.
Five patients underwent reoperation, but did not receive repeat radiotherapy or chemotherapy. Survival times after reoperation were short. One patient died during the immediate postoperative period, the others
Histological Studies
Tumors were classified according to the four-grade WHO system proposed by Zfilch. 17 The most malignant variety (Grade 4) was defined as glioblastoma, whereas all astrocytomas with malignant characteristics were classified as malignant astrocytoma (Grade 3). The overwhelming majority of cases in this series belonged to the glioblastoma group. The ratio of malignant astrocytomas was nearly equal in all three groups (23% to 28%). All tumors were reclassified before final evaluation, and in dubious cases were also reviewed by a second neuropathologist.
Results
Clinical Data
A total of 91 patients entered the study and were randomized to one of the three treatment arms. Seven patients had to be excluded from final evaluation because of protocol violation. Reasons of protocol violations are listed in Table 2 . The series included all patients who received at least one complete course of radiotherapy with or without DBD during irradiation. One patient in Group 2 did not receive any subsequent courses of DBD; two others from Group 2 and three from Group 3 were treated with one course only, because of rapid recurrence of their disease. All other patients received two to 10 courses of chemotherapy following irradiation (Table 3 ). The mean single dose of DBD was 400.2 mg (range 347 to 441 mg), and, in combination therapy, the mean single dose of CCNU was 95 mg (range 78 to 108 mg) and of DBD was 222 mg (range 166 to 303 mg).
The most important data from 84 evaluated patients are summarized in Table 4 . The figures display an approximately even distribution of parameters in the three groups. The only exception is the predominance of females in Group 3. The other factors, which are supposed to have some influence on prognosis, such as age, location of tumor, Karnofsky Scale score, and number of malignant astrocytomas, did not show any striking difference. In addition, we would like to emphasize the uniformity of surgery and the direct control of patients, which was due to the fact that all but six patients were operated on and treated in one institution.
Toxicity
Irradiation by itself and radiotherapy combined with DBD alone did not produce any toxic side-effects on bone marrow, and the planned DBD dose could be delivered during irradiation in patients from both Groups 2 and 3. Gastrointestinal toxicity during the same treatment was negligible, and the mild nausea that occasionally occurred could be sufficiently suppressed by small doses of antiemetic drugs. Similarly, only a mild myelotoxicity was observed during DBD treatment subsequent to radiotherapy. A decrease ofplatelet and white blood cell (WBC) count below a critical level never occurred. With some patients, a transient drop of both values was found after single courses of therapy at 4 weeks, on the average, but the values had returned to normal by the time of the next course. Dose reduction was not necessary. One patient complained of skin rashes after the first DBD course, so drug administration had to be stopped.
The combination of CCNU and DBD (Group 3) proved to be much more myelotoxic than DBD alone. Nearly each course was followed by a severe decline of WBC and platelet counts 4 to 6 weeks after the course began. In the majority of cases these counts were restored until the next course. Although we reduced the initial dose of CCNU to 80 to 90 mg/sq m during the trial, in three cases a transient dose reduction of 25% to 50% was required, and in three other patients chemotherapy had to be stopped for 4 to 6 weeks. Blood transfusion and supportive therapy were used sporadically only when platelet count and WBC's decreased below 25,000 or 1500, respectively (Table 5) . At the same time, no clinical signs of myelotoxicity occurred and no patient was lost because of irreversible damage to the hematopoetic system. In contrast to DBD, CCNU caused transient nausea and vomiting in the majority of patients. However, treatment could be continued in all cases.
Survival T i m e
The last patient entered the study in February, 1981, and the observation period was closed on April 30, 1982. Although some patients are still alive, their actual length of survival will not change the median value obtained, and only minor changes are to be expected in survival at 18 and 24 months. Therefore, a statistical evaluation is already possible.
Patients who received radiotherapy alone had a median survival period of 40 weeks, and one is still alive. The median survival time in Groups 2 and 3 with adjunctive chemotherapy was 57 and 60 weeks, respectively. Both drug-treated groups showed a significantly better survival period than patients who were only irradiated (p = 0.0246 and 0.0015, respectively; Fig. 1 ). The survival curve of Group 3 seems to be somewhat better than that of Group 2, but the difference is only marginal (p < 0.99). On the other hand, the number of survivors for longer than 18 and 24 months, and of patients still alive is highest in Group 3 ( Table 6 ).
Discussion
Among a wide variety of different cytostatic agents, the nitrosoureas have seemed to be the most effective drugs against brain gliomas, whether given alone, in combination with other chemotherapy, or in combination with irradiation. ~~ Walker, et aL, ~5 found that BCNU ( 1,3-bis(2-chloroethyl)-1-nitrosourea) given with irradiation prolonged the median survival period by a few weeks only, without significant difference compared to radiotherapy alone (40.5 compared with 37.5 weeks). The European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group evaluated in 1976 the effect ofCCNU, 1~ and in 1981 a combination ofCCNU, VM-26, and procarbazine 12 in the treatment of supratentorial gliomas. The adjuvant chemotherapy improved survival times only slightly; it proved to be more effective if chemotherapy was given at the time of recurrence. In a prospective, randomized trial, Walker, et al., J6 compared BCNU and Me-CCNU as adjunctive therapy with irradiation versus radiotherapy alone. Neither drug significantly improved the median survival times of malignant glioma patients (51 and 42 weeks compared with 36 weeks for radiotherapy alone); however, the number of longer survivors was higher. They concluded that the most important treatment of malignant gliomas is radiotherapy, and no significant difference in survival time can be achieved with concurrent chemotherapy with nitrosoureas. Edwards, et al., 1~ surveyed the agents in current use in brain-tumor chemotherapy, and stated that "irradiation followed by BCNU continues to be the standard treatment." At the same time, they emphasized that there is a need for evaluation of other drugs and new combination therapy.
Hexitol derivatives, especially DBD and its main metabolite, DAG, have an antitumor activity against several kinds of malignancies. 8 Both compounds easily cross the blood-brain barrier and accumulate in tumor tissue, 9 although DBD does not do so selectively. 5 Eagan, et al.,6 used DAG with irradiation in a randomized trial and achieved a significantly better median survival period compared to radiotherapy alone (67 compared to 35 weeks). A combination of DAG with VP-16 and triazinate (TZT) proved to be effective in the treatment of glioma recurrences as well. 7 In our previous studies, DBD showed some activity against brain tumors, even when given alone, but promising results could be obtained by simultaneous irradiation. ~ With combined BCNU and DBD chemotherapy, we obtained a 50% response rate in the treatment of malignant glioma recurrences. 2 In this study, we wanted to obtain more extensive data about the activity of DBD in combined therapy. As radiotherapy is indispensable in the postoperative treatment of gliomas, irradiation was delivered to all patients. Group 2 and 3 patients received the same schedule during irradiation, but the subsequent chemotherapy was different. In one arm of the trial, treatment was continued with DBD alone and in another arm CCNU was administered in addition to DBD. We chose CCNU among the nitrosoureas because it is less toxic and can be delivered orally.
The number of patients and the nearly identical distribution of the most important clinical parameters permit a statistical evaluation. This is supported by the fact that operative rationale and treatment moralities were uniform, because the vast majority of patients were operated on and treated at the same institution. Factors that are supposed to influence prognosis (age, location of tumor, histology, sex, and Karnofsky Performance Scale score, among others) were evenly represented in each group.
Regarding both survival curves and percentages of longer survivors, radiotherapy combined with DBD or with DBD and CCNU resulted in a significantly better survival than irradiation alone. Addition of CCNU to DBD treatment improved the results only marginally, but involved a more severe myelotoxicity. The median survival values of 57 and 60 weeks for the treated groups are at least equal or superior to those achieved with nitrosoureas.
In evaluating the possible role of single factors in this complex therapeutic regimen, several current and earlier experiences must be taken into consideration. Combined treatment with DBD and CCNU did not significantly influence survival times; on the other hand, DBD alone had only a moderate effect in our previous experience. Finally, patients who received DBD during irradiation only were included in the evaluated group. On the basis of these observations, it can be assumed that the concurrent use of DBD during irradiation was the main factor in improving survival significantly. Whether DBD has a potentiating effect or whether it works as a real radiosensitizer cannot be decided at present. The encouraging clinical results, as well as questions regarding the mechanism of the effect of DBD necessitate further extended clinical trials and laboratory investigations.
